» Articles » PMID: 34491463

Models of Pancreatic Ductal Adenocarcinoma

Overview
Specialty Oncology
Date 2021 Sep 7
PMID 34491463
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Although pancreatic cancer remains to be a leading cause of cancer-related deaths in many industrialized countries, there have been major advances in research over the past two decades that provided a detailed insight into the molecular and developmental processes that govern the genesis of this highly malignant tumor type. There is a continuous need for the development and analysis of preclinical and genetically engineered pancreatic cancer models to study the biological significance of new molecular targets that are identified using various genome-wide approaches and to better understand the mechanisms by which they contribute to pancreatic cancer onset and progression. Following an introduction into the etiology of pancreatic cancer, the molecular subtypes, and key signaling pathways, this review provides an overview of the broad spectrum of models for pancreatic cancer research. In addition to conventional and patient-derived xenografting, this review highlights major milestones in the development of chemical carcinogen-induced and genetically engineered animal models to study pancreatic cancer. Particular emphasis was placed on selected research findings of ligand-controlled tumor models and current efforts to develop genetically engineered strains to gain insight into the biological functions of genes at defined developmental stages during cancer initiation and metastatic progression.

Citing Articles

The Janus kinase 1 is critical for pancreatic cancer initiation and progression.

Shrestha H, Radler P, Dennaoui R, Wicker M, Rajbhandari N, Sun Y Cell Rep. 2024; 43(5):114202.

PMID: 38733583 PMC: 11194014. DOI: 10.1016/j.celrep.2024.114202.


Cellular Plasticity in Mammary Gland Development and Breast Cancer.

Wicker M, Wagner K Cancers (Basel). 2023; 15(23).

PMID: 38067308 PMC: 10705338. DOI: 10.3390/cancers15235605.


Single-cell mapping identifies MSI cells as a common origin for diverse subtypes of pancreatic cancer.

Rajbhandari N, Hamilton M, Quintero C, Ferguson L, Fox R, Schurch C Cancer Cell. 2023; 41(11):1989-2005.e9.

PMID: 37802055 PMC: 10836835. DOI: 10.1016/j.ccell.2023.09.008.


Pancreatic Organoids: A Frontier Method for Investigating Pancreatic-Related Diseases.

Liu Y, Li N, Zhu Y Int J Mol Sci. 2023; 24(4).

PMID: 36835437 PMC: 9959977. DOI: 10.3390/ijms24044027.


Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries.

Hemminki K, Forsti A, Hemminki O, Liska V, Hemminki A JHEP Rep. 2022; 4(12):100602.

PMID: 36352895 PMC: 9638835. DOI: 10.1016/j.jhepr.2022.100602.


References
1.
Li K, Yang J, Chen J, Shi Y, Zhang Z, Chen W . High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncol Lett. 2020; 19(2):1584-1592. PMC: 6956425. DOI: 10.3892/ol.2019.11205. View

2.
Lakso M, Sauer B, Mosinger Jr B, Lee E, Manning R, Yu S . Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A. 1992; 89(14):6232-6. PMC: 49474. DOI: 10.1073/pnas.89.14.6232. View

3.
Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

4.
Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

5.
Fukuda A, Wang S, Morris 4th J, Folias A, Liou A, Kim G . Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011; 19(4):441-55. PMC: 3075548. DOI: 10.1016/j.ccr.2011.03.002. View